Inhaled albuterol powder for pulmonary function testing
| Autor: | Erik van Lunteren, Albert Coreno |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.drug_class Vital Capacity Powder dose form Critical Care and Intensive Care Medicine Airflow obstruction Pulmonary function testing FEV1/FVC ratio Bronchodilator Forced Expiratory Volume Isoetharine Medicine Humans Albuterol Aerosols business.industry Respiratory disease respiratory system medicine.disease respiratory tract diseases Respiratory Function Tests Anesthesia Powders Cardiology and Cardiovascular Medicine business circulatory and respiratory physiology |
| Zdroj: | Chest. 101(4) |
| ISSN: | 0012-3692 |
| Popis: | To assess the role of albuterol powder in testing for reversibility of airflow obstruction during routine pulmonary function testing, spirometric data from subjects with baseline FEV1/FVC less than 70 percent and FEV1 less than 80 percent predicted who received inhaled albuterol powder (n = 42) were compared with those who received isoetharine aerosol via metered dose inhaler (n = 49). Prebronchodilator lung function was comparable for the albuterol and isoetharine groups. With albuterol powder, 14 (33 percent) of 42 subjects showed reversibility of airflow obstruction (defined as a 15 percent or greater improvement in either FEV1 or FVC) as compared with 30 (61 percent) of 49 subjects with isoetharine aerosol. The significantly (p less than 0.01) lower rate of improvement with albuterol powder was especially prominent in subjects with moderate airflow obstruction (FEV1/FVC of 45 to 59 percent). These data do not support the substitution of inhaled albuterol powder for isoetharine aerosol in assessing for reversibility of airflow obstruction during routine pulmonary function testing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|